Minimizing drug container interactions with 100% compliance
Recent data has shown a decrease in glass related recalls in the marketplace. Gains can partially be attributed to pharmaceutical companies and their suppliers working together to identify the correct drug container combinations, especially as converting technology has enabled the introduction of a variety of approaches to investigate.
Nipro PharmaPackaging has taken the unique approach to utilize Type 1 borosilicate glass without introducing any radical formulation changes, or employing the use of any harsh chemical washing or exotic coatings that significantly increase cost. Delivering 100% all points in compliance also acts to create a true differentiator with VIALEXâ„¢. Attendees will learn how VIALEXâ„¢ meets all of the industry’s concerns and also understand the proprietary technology only recently shared with the industry.
Continued characterization studies and evaluations of VIALEXâ„¢ will be shared along with case studies demonstrating the superior inner surface durability not previously known in tubular glass vials. Whether its pH control, an increase in shelf life, a lower level of extractables, or the need to reduce the risk of delamination, VIALEXâ„¢ stands out as THE solution to include in drug development studies or to apply to an existing drug product without the need to revalidate.
Presented by
Dave Lisman,
Strategic Project Manager
Dave has over a decade of experience with Nipro serving in a variety of positions from project manager to Plant Manager of several facilities.
His current role as Strategic Project Manager aims to deliver technical solutions that increase the value proposition to Nipro’s customers in response to industry challenges of both today and tomorrow.
Dave received a B.S. in Chemical Engineering from Bucknell University and an M.B.A from the Kelley School of Business of IU.